Monday, May 26th.

Taking advantage of the presence of the presidents of the group's subsidiaries, Zhang Shuo personally hosted this week's meeting, which can be regarded as a rare offline group high-level meeting.

The newcomer, Sun Yang, president of Qing Ning Group, was the first to report.

"Previously, the chairman of the board of directors instructed that Qing Ning Group's next goal is to get involved in the field of medical devices, and plans to select one or two medical device companies with certain technical capabilities as acquisition targets."

"I have chosen one here just for everyone to discuss."

Sun Yang acted very modestly. After a simple opening remarks, he started to show the ppt.

"The company's name is Weichuang Medical. It is headquartered in Shanghai and was founded in 1998. It is considered a leading high-end medical device group in China."

"The founder, Dr. Chen, is an expert in the field of minimally invasive medical devices in China."

"Weicron Medical's business mainly covers cardiovascular interventional products, orthopedic medical devices, aortic and peripheral vascular interventional products and other fields."

“Among them, it is mainly based on cardiovascular interventional products and is a leader in the field of minimally invasive medical devices.”

"Weichuang will be listed in Xiangjiang in 10 years."

"The years before and after the listing were also the years when Weichuang made great strides in development. In 2008, Weichuang Life Technology was established, entered the field of diabetes, and launched a diversified strategic layout."

"Weicron Orthopedics was established in 2009, Weicron Electrophysiology was established in 2010, and Weicron Shentong, Weicron Cardiac, and Weicron surgical equipment were established in 2012. Recently I heard that Weicron Medical is actively planning to establish Weicron Medical Robot

, Weichuang Online Medical Technology and other subsidiaries.”

"Isn't this step a bit big?" Zhang Shuo frowned.

After listening to Sun Yang's introduction, he finally had an impression of the medical company Weichuang. Yuanshikong has attracted much attention due to its "Calabash" model of spinning off subsidiaries and packaging them for listing.

In addition to Vitron Medical itself being listed in Xiangjiang, there are actually five listed companies under its umbrella.

Each listed company corresponds to one main business.

The problem is that most of the new businesses that Weichuang develops or the subsidiaries that it spins off and list are in a state of loss. Only a few subsidiaries can actually achieve profitability, and they all rely on blood transfusions from the parent company.

The parent company faces the risk of "hollowing out".

This also leads to the saying that although Weichuang had its glory days in the stock market, its prototype soon appeared again.

"A little bit."

Sun Yang did not deny it, "As far as I know, Dr. Chen is a very ambitious person and wants to develop Weichuang into a platform-based medical device group, so he chose a diversified development route. If only Weichuang itself

It is impossible to complete the diversification strategy without the strength of the company, and it needs to rely on the power of capital."

"oh?"

Zhang Shuo raised his eyebrows slightly, understanding the underlying meaning of Sun Yang's words.

Weichuang Medical has great ambitions, but its own strength is not strong enough. It needs to rely on the power of external capital. With Qing Ning Group backed by the big tree of Germination, the most important thing it lacks is capital.

The two hit it off right away.

"What is the current market value of Weichuang Medical and what is its equity structure?" Zhang Shuo asked with concern.

"The current market value is about 6.5 billion, and the ownership structure is relatively concentrated. In addition to the circulating shares on the market, the rest are mainly concentrated in the hands of a few major shareholders, including an investment company from Japan."

Sun Yang has obviously done his homework.

"Sixty-five billion is not expensive!"

It is rare for Zhang Shuo to visit Versailles. After all, with the current financial strength of the Sprout Group, any acquisition with an amount of less than 10 billion can only be regarded as a small event.

And if he remembered correctly, the market value of Yuanshikong Weichuang Medical exceeded 100 billion at its peak. Even during the period of underestimation, it still had a market value of 20 to 30 billion.

This does not include the other five listed companies that were independently spun off and listed.

You should know that the total market value of these five spin-off listed companies was once close to the stock price of the parent company. The founder, Dr. Chen, even shouted the slogan of a trillion market value.

Although it’s a bit bragging, it’s just...

Regarding the future stock price of Weichuang, it means that even from a purely financial investment perspective, the acquisition of Weichuang is a relatively cost-effective deal.

At least it’s not a loss!

"Let's see, I have two requirements for the acquisition of Weichuang."

Zhang Shuo thought for a moment and said: "First, the prerequisite for the acquisition is that Weichuang wants to delist from the privatization of Xiangjiang. Second, it must be ensured that all the equity in the Japanese company's hands is taken over."

"If the Weichuang board of directors is willing to accept these two conditions, the acquisition process can be started."

In Zhang Shuo's inherent understanding, the stock market, market value, etc. are actually all fictitious.

Take the U.S. stock market as an example. Tesla's market value exceeded one trillion U.S. dollars, and Vinda's market value once exceeded 800 billion U.S. dollars. At its peak, the market value was several times, or even more than ten times, that of Broadcasting.

But if you want to trade broadcasting for Texila, I guess no one would be stupid enough to do so.

There are similar examples in China. For example, Linde New Energy of the original time and space had a market value of nearly 1.5 trillion at its peak, but the net profit attributable to the parent company that year was only about 1.5 billion.

It doesn't match at all.

To put it bluntly, stock prices are often irrational and play on concepts. Most of the time they are out of touch with actual operating conditions and become a pure capital game.

Therefore, Zhang Shuo has never been enthusiastic about promoting the company's listing.

Of course, this is also related to the support he has from the system. He has basically never been short of money since the beginning of his business, and this will be even more true after the game business gets on the right track.

on the other hand.

It was also because of the rapid development of the sprout that Zhang Shuo's net worth skyrocketed too quickly. He had no interest or need to evaluate his personal assets through the so-called market value and compete for the title of the richest man.

It's quite a bit like being alone and seeking defeat.

Not only is Weichuang going to be privatized and delisted, but Hengrui Pharmaceutical, which still maintains its listing status, Zhang Shuo also plans to complete the privatization of Hengrui Pharmaceutical when the time is right in the future.

Of course, privatization does not mean that Qing Ning Group will have 100% control.

This chapter is not finished yet, please click on the next page to continue reading the exciting content! Even if it is privatized, the major shareholders of Hengrui Pharmaceuticals, headed by Sun Yang, can still hold shares of Hengrui Pharmaceuticals, but they no longer need to accept

Supervision of listed institutions.

There is no longer any need to be responsible to investors and excessive pursuit of investment returns.

Instead, it focuses on R&D and is based on the long-term strategy of corporate development rather than short-term gains. Only in this way can Hengrui Pharmaceuticals become one of the giants in the global pharmaceutical industry in the future.

"good!"

This time, the person who nodded in agreement was Luo Changan, the investment director in charge of the group's investment business.

After Lu Kai was promoted to the group president, Luo Changan took charge of the group's investment and mergers and acquisitions business, including preliminary investigations, contacts, and even mid- and late follow-up.

It's just that at the critical moment, Lu Kai needs to step in and play the decisive role.

Similar to Zhang Shuo before.

Of course, Lu Kai was not a freeloader. Taking advantage of the topic of acquiring a medical device company, he said: "Chairman, the Investment and Acquisition Department has also locked in a medical device company, which is local to Binhai City."

"Oh, tell me?"

Given the size of Weichuang, it may not be able to fully satisfy the Qing Ning Group’s appetite.

"Is such that."

Lu Kai opened the ppt with a smile and introduced: "This company is called Marui Medical. It was founded in 1991 and was listed in the United States in 2006. It became the first medical equipment company in China to be listed in the United States."

It can be found that the old medical companies were basically established in the 1980s and 1990s.

"Marui's main business covers the three major medical device fields of life information and support, in vitro diagnosis, and medical imaging, and has gradually expanded to animal medicine, minimally invasive surgery, orthopedic consumables and other fields."

“In the field of life information and support, the main products include monitors, defibrillators, anesthesia machines, ventilators, electrocardiographs, operating beds, operating lights, pendant bridges, infusion pumps, and overall solutions for operating rooms/intensive care units.

solutions and a series of instruments and solutions for life information monitoring and support, as well as products including surgical endoscopic camera systems, cold light sources, infessers, optical endoscopes, minimally invasive surgical instruments and surgical consumables.

A series of minimally invasive surgical products.”

“In the field of in vitro diagnostics, we mainly provide a series of fully automatic and semi-automatic in vitro diagnostic products for laboratories, clinics and hospitals, mainly including blood cell analyzers, biochemical analyzers, chemiluminescence immunoassay analyzers, coagulation analyzers, and urinalysis

Instruments, microbial diagnostic systems, and related reagents are used to obtain clinical diagnostic information through the detection of human samples."

“In the field of medical imaging, the main products include ultrasound diagnostic systems, digital

radiography systems and

In the field of ultrasonic diagnostic systems, pacs. provides hospitals, clinics, imaging centers, etc. with a full range of ultrasonic diagnostic systems from high-end coverage to low-end, and gradually subdivides them into applications in radiology, obstetrics and gynecology, interventional, emergency, anesthesia, critical care, liver

Dedicated solutions for different clinical specialties such as fiber optics. In digital x

In the field of radiography, we mainly provide a variety of digital imaging solutions, including mobile, double-column and suspended, for radiology departments, ICUs, and emergency departments."

"It can be said that Marui is China's leading enterprise in medical device production."

"so smart?"

Zhang Shuo's brows raised slightly. He really didn't expect that there would be such a giant in Binhai City.

"I have investigated the history of Marian's fortune. Since it went public in the United States in 2006, it has embarked on a crazy journey of mergers and acquisitions. It has made up for its shortcomings in the business by acquiring related companies at home and abroad."

Lu Kai explained with a smile.

"Especially in 2008, 2011, 2012, and 2013, including this year, there were large-scale mergers and acquisitions."

In the development process of medical device companies, mergers and acquisitions are one of the basic paths. Looking at the leading companies in the global medical device industry, without exception, they have grown into industry giants through mergers and acquisitions.
To be continued...